

Shang Zhongyang
Form 3
April 22, 2013

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB
Number: 3235-0104
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting
Person *

Â Shang Zhongyang

(Last) (First) (Middle)

C/O BIOSTAR
PHARMACEUTICALS,
INC.,Â NO. 588 SHIJI AVENUE

(Street)

XIANYANG,Â F4Â 712046

(City) (State) (Zip)

2. Date of Event Requiring
Statement

(Month/Day/Year)

12/30/2009

3. Issuer Name **and** Ticker or Trading Symbol
Biostar Pharmaceuticals, Inc. [BSPM]

4. Relationship of Reporting
Person(s) to Issuer

5. If Amendment, Date Original
Filed(Month/Day/Year)

(Check all applicable)

☒ Director ☐ 10% Owner
☐ Officer ☐ Other
(give title below) (specify below)

6. Individual or Joint/Group
Filing(Check Applicable Line)
☒ Form filed by One Reporting
Person
☐ Form filed by More than One
Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security
(Instr. 4)

2. Amount of Securities
Beneficially Owned
(Instr. 4)

3. Ownership
Form:
Direct (D)
or Indirect
(I)
(Instr. 5)

4. Nature of Indirect Beneficial
Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form displays a
currently valid OMB control number.**

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 4)

2. Date Exercisable and
Expiration Date
(Month/Day/Year)

Date Expiration
Exercisable Date

3. Title and Amount of
Securities Underlying
Derivative Security
(Instr. 4)

Title Amount or
Number of

4. Conversion
or Exercise
Price of
Derivative
Security

5. Ownership
Form of
Derivative
Security:
Direct (D)

6. Nature of Indirect
Beneficial
Ownership
(Instr. 5)

Edgar Filing: Shang Zhongyang - Form 3

				Shares		or Indirect (I) (Instr. 5)	
Options to purchase common stock ⁽¹⁾	12/31/2009	12/30/2014	Common stock	16,667	\$ 13.35	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Shang Zhongyang C/O BIOSTAR PHARMACEUTICALS, INC. NO. 588 SHIJI AVENUE XIANYANG,Â F4Â 712046	Â X	Â	Â	Â

Signatures

/s/ Zhongyang
Shang

04/22/2013

 Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This option was issued pursuant to the Company's 2009 Incentive Stock Plan and Incentive Stock Option Agreement dated as of December 30, 2009. On a post reverse split basis, the number of shares purchasable under this option is adjusted to 16,667 shares and its

(1) exercise price is adjusted to \$13.35. The option shall become exercisable during the term of the Reporting Person's employment in three equal annual installments, the first installment to be exercisable on the date of grant (the "Initial Vesting Date"), with additional installments becoming exercisable on each of the successive anniversaries following the Initial Vesting Date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.